As the lot number for the device was not provided, a manufacturing review could not be performed.The sample was not returned to the manufacturer for inspection/evaluation.Therefore, the investigation of the reported event is inconclusive.Based upon the available information, the definitive root cause for this event is unknown.The instructions for use (ifu) is adequate for the reported device/patient code(s) and provides general instructions for use, as well as warnings, precautions and potential complications associated with the device.Upon receipt of new or additional information, a follow-up report will be submitted as applicable.Journal article citation: gray, k.L., steidley, i.G., benson, h.L., pearce, c.L., bachman, a.M., and adamski, j.(2019, september 4).Implementation and 2-year outcomes of the first fda-approved implantable apheresis vascular access device.Retrieved from https://onlinelibrary.Wiley.Com/doi/pdf/10.1111/trf.15512.
|
It was reported in an article from the journal of transfusion titled " implementation and 2-year outcomes of the first fda-approved implantable apheresis vascular access device " that a total of eighteen patients underwent apheresis treatment during the study period.Two patients experienced infection as the blood culture came positive, therefore the ports were removed and the infection was treated with antibiotic and supportive therapy.In one patient, the catheter was unable to aspirated and even after administrating alteplase the line did not clear the obstructed flow; dye study confirmed that the catheter tip migrated into the azygous vein and this prevented the use of the port.Catheter tip migrated in another patient but due to completion of the treatment, repositioning was not performed.The status of the patients was not provided.
|